Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Prior treatment

• Prior exposure to seladelpar
• Evidence of portal vein thrombosis based on imaging at time of Screening by Doppler ultrasound or prior evidence by CT or MRI
• History or presence of other concomitant liver diseases

Other illness

• A medical condition other than PBC that, in the Investigator's opinion, would preclude full participation in the study
• History of liver transplantation or actively listed for cadaveric or planned living donor transplant.

Lab values

• Laboratory parameters at Screening:
  • Alkaline phosphatase (ALP) \< 1.5× Upper limit of normal (ULN) or ≥ 10×ULN
  • Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≥5×ULN
  • Total bilirubin (TB) ≤ 0.6 × ULN or ≥ 5 × ULN
  • Platelet count ≤50×10\^3/µL
  • Albumin ≤2.8 g/dL
  • Estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m\^2
  • MELD score \>12. For individuals on anticoagulation medication, baseline International normalized ratio (INR) determination for MELD score calculation should take anticoagulant use into account, in consultation with the Medical Monitor.
  • Serum alpha-fetoprotein (AFP) \>20 ng/mL
  • INR \>1.7

Other

• Individuals must not meet any of the following criteria to be eligible for study participation:
• Decompensated cirrhosis
• Hospitalization for liver-related complication within 12 weeks of Screening
• CP-C cirrhosis

• Individuals must meet the following criteria to be eligible for study participation:
• Must be at least 18 years old.
• Must have a confirmed prior diagnosis of primary biliary cholangitis (PBC)
• Evidence of cirrhosis
• CP Score A or B
• Females of reproductive potential must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male individuals who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose
• Individuals must be able to comply with the instructions for study drug administration and be able to complete the study schedule of assessments (SOA)